Loading clinical trials...
Loading clinical trials...
Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)
The objective of this survey is to confirm the safety of Suglat Tablets
The objective of this survey is to confirm the safety and efficacy of Suglat Tablets for long-term use over 3 years. Specify the effects of Suglat Tablets on the cardiovascular system, incidence rates of malignant tumor, and their risk factors. Investigate the occurrence of adverse drug reactions. Specify factors that may possibly influence the safety and efficacy of Suglat Tablets. \<Items of interest\> * Hypoglycemia * Genital infection * Urinary tract infection * Polyuria and pollakiuria * Adverse events related to a decrease in body fluids (dehydration, etc.) * Malignant tumor * Cardiovascular diseases
Age
All ages
Sex
ALL
Healthy Volunteers
No
Chugoku, Japan
Chūbu, Japan
Hokkaido, Japan
Kansai, Japan
Kantou, Japan
Kyushu, Japan
Shikoku, Japan
Tōhoku, Japan
Start Date
July 17, 2014
Primary Completion Date
October 16, 2018
Completion Date
October 16, 2018
Last Updated
October 22, 2024
11,412
ACTUAL participants
ipragliflozin
DRUG
Lead Sponsor
Astellas Pharma Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587